Improving outcomes through comprehensive controlled substance monitoring - Insights
Controlled substance testing options vary in the details they provide about patient drug use, painting an incomplete picture of usage patterns that can hinder accurate prescription monitoring and treatment outcomes. However, a new...
Peroxisomal biogenesis and metabolism - Insights
Learn more about how Mayo Clinic Laboratories’ testing for peroxisomal biogenesis and metabolism disorders can assist in the identification of these sometimes fatal conditions.
https://news.mayocliniclabs.com/mc2775-782/
FO U R RE AL -W O RL D C O LL AB O RA TI VE E XA M PL ES to Mayo Clinic diagnostics C O N N E C T I N G Pharma and biotech TABLE OF CONTENTS What makes a good testing partner? Case study 1 Gastrointestinal study collects and tests...
Allan Jaffe, M.D., Consultant and Chair of Mayo Clinic’s Division of Clinical Core Laboratory Services, with a joint appointment in the Division of Cardiovascular Diseases, will be presenting a webinar on the implementation of a...
IGHV and TP53 Sequencing: Clinical Utility in Chronic Lymphocytic Leukemia (CLL) - Insights
In this month’s “Hot Topic,” Curtis Hanson, M.D., will discuss the use of laboratory-based prognostic markers in patients with chronic lymphocytic leukemia (CLL). He will also highlight the importance of molecular analyses for IGHV and TP53...
Mayo Clinic has been recognized as the No. 1 gastroenterology and gastrointestinal surgery hospital in the nation by U.S. News & World Report every year since 1990. Backed by the experience and knowledge of more than 140 digestive disease...
Developed through evidence-driven clinical innovation and designed to deliver clarity on drug and alcohol use, our testing delivers results that advance understanding and improve outcomes.
Patient-focused pragmatism: The Mayo Clinic innovation model - Insights
In a world of ever-faster technical change, Mayo Clinic Laboratories is uniquely positioned to innovate. Collaboration with clinicians pinpoints unmet patient needs and facilitates the development of diagnostic testing that provides...
Improving diagnosis of rare congenital disorders - Insights
Experts at Mayo Clinic have developed a unique method of testing that combines new technology with novel bioinformatics to promptly detect a group of uncommon genetic conditions that are often difficult to identify.
Testing for a surprising antigen enables insight into a chronic kidney illness - Insights
Mayo Clinic renal pathologist Dr. Sanjeev Sethi identified NELL-1 as a biomarker for membranous nephropathy (MN) in 2019. Two years later, Dr. Sethi helped implement the first ever IHC test to detect NELL-1 antigen, which appears in about...